亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial

医学 利福昔明 肝纤维化 双盲 安慰剂 内科学 肝病 胃肠病学 纤维化 病理 化学 生物化学 替代医学 抗生素
作者
Mads Israelsen,Bjørn Stæhr Madsen,Nikolaj Torp,Stine Johansen,Camilla Dalby Hansen,Sönke Detlefsen,Peter Andersen,Johanne Kragh Hansen,Katrine Prier Lindvig,Ditlev Nytoft Rasmussen,Katrine Holtz Thorhauge,Maria Kjærgaard,M.A. Karsdal,Torben Hansen,Manimozhiyan Arumugam,Jonel Trebicka,Maja Thiele,Aleksander Krag,Ema Anastasiadou,Manimozhiyan Arumugam
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:8 (6): 523-532 被引量:50
标识
DOI:10.1016/s2468-1253(23)00010-9
摘要

BACKGROUND: Alcohol is the leading cause of liver-related mortality worldwide. The gut-liver axis is considered a key driver in alcohol-related liver disease. Rifaximin-α improves gut-barrier function and reduces systemic inflammation in patients with cirrhosis. We aimed to compare the efficacy and safety of rifaximin-α with placebo in patients with alcohol-related liver disease. METHODS: GALA-RIF was an investigator-initiated, randomised, double-blind, placebo-controlled, single-centre, phase 2 trial done at Odense University Hospital in Denmark. Eligible participants were adults (aged 18-75 years) who had current or previous alcohol overuse (at least 1 year with ≥24 g of alcohol per day for women and ≥36 g of alcohol per day for men), biopsy-proven alcohol-related liver disease, and no previous hepatic decompensation. Patients were randomly allocated (1:1) through a web-based randomisation system to receive oral rifaximin-α (550 mg) twice daily or matched placebo for 18 months. Randomisation was done in blocks of four and stratified according to fibrosis stage and alcohol abstinence. Participants, sponsor, investigators, and nurses involved in the study were masked to the randomisation outcome. The primary endpoint was a histological decrease from baseline to 18-month treatment of at least one fibrosis stage, according to the Kleiner fibrosis score. We also assessed the number of patients with progression by at least one fibrosis stage from baseline to 18 months. Primary analyses were done in the per-protocol and modified intention-to-treat populations; safety was assessed in the full intention-to-treat population. The per-protocol population was defined as all randomly assigned patients who did not present serious protocol violations, who ingested at least 75% of the treatment, and who were not withdrawn from the study due to non-adherence (interruption of treatment for 4 weeks or more). Participants receiving at least one dose of the intervention were included in the modified intention-to-treat analyses. This completed trial is registered with EudraCT, number 2014-001856-51. FINDINGS: Between March 23, 2015, and Nov 10, 2021, we screened 1886 consecutive patients with a history of excessive alcohol consumption and no previous hepatic decompensation, of whom 136 were randomly assigned to either rifaximin-α (n=68) or placebo (n=68). All patients were White (100%), 114 (84%) were men, and 22 (16%) were women. 133 (98%) patients received at least one dose of the intervention and were included in the modified intention-to-treat analysis; 108 (79%) completed the trial per protocol. In the per-protocol analysis, 14 (26%) of 54 patients in the rifaximin-α group and 15 (28%) of 54 patients in the placebo group had a decrease in fibrosis stage after 18 months (odds ratio 1·10 [95% CI 0·45-2·68]; p=0·83). In the modified intention-to-treat analysis, 15 (22%) of 67 patients in the rifaximin-α group and 15 (23%) of 66 patients in the placebo group had a decrease in fibrosis stage at 18 months (1·05 [0·45-2·44]; p=0·91). In the per-protocol analysis, increase in fibrosis stage occurred in 13 (24%) patients in the rifaximin-α group and 23 (43%) patients in the placebo group (0·42 [0·18-0·98]; p=0·044). In the modified intention-to-treat analysis, increase in fibrosis stage occurred in 13 (19%) patients in the rifaximin-α group and 23 (35%) patients in the placebo group (0·45 [0·20-1·02]; p=0·055). The number of patients with adverse events (48 [71%] of 68 patients in the rifaximin-α group; 53 [78%] of 68 in the placebo group) and serious adverse events (14 [21%] in the rifaximin-α group; 12 [18%] in the placebo group) was similar between the groups. No serious adverse events were deemed related to treatment. Three patients died during the trial, but none of the deaths were considered treatment related. INTERPRETATION: In patients with alcohol-related liver disease, rifaximin-α might reduce progression of liver fibrosis. These findings warrant confirmation in a multicentre phase 3 trial. FUNDING: The EU Horizon 2020 Research and Innovation Program and The Novo Nordisk Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
3秒前
浮云发布了新的文献求助10
6秒前
芒果完成签到,获得积分20
7秒前
15秒前
19秒前
浮云发布了新的文献求助10
23秒前
23秒前
34秒前
40秒前
复杂曼荷完成签到,获得积分10
42秒前
may完成签到 ,获得积分10
44秒前
52秒前
53秒前
英俊的铭的应助被邓倩采纳,获得10
53秒前
Maestro_S的应助被呵呵采纳,获得10
57秒前
00hello00发布了新的文献求助10
1分钟前
1分钟前
1分钟前
仁爱的鞋子完成签到,获得积分10
1分钟前
安详老鼠完成签到,获得积分10
1分钟前
1分钟前
1分钟前
Shu完成签到,获得积分10
1分钟前
刻苦的煎蛋完成签到,获得积分10
1分钟前
庾傀斗发布了新的文献求助10
1分钟前
ssgg完成签到,获得积分10
1分钟前
辛勤诗兰完成签到,获得积分10
1分钟前
1分钟前
不爱写论文完成签到,获得积分10
1分钟前
HaoZhang发布了新的文献求助10
1分钟前
2分钟前
Lynee完成签到,获得积分10
2分钟前
清脆妙梦完成签到,获得积分10
2分钟前
sugar发布了新的文献求助10
2分钟前
小辣椒完成签到,获得积分10
2分钟前
HaoZhang完成签到,获得积分20
2分钟前
尊敬康乃馨完成签到,获得积分10
2分钟前
初景发布了新的文献求助10
2分钟前
zhaodan完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195111
求助须知:如何正确求助?哪些是违规求助? 9580886
关于积分的说明 21872823
捐赠科研通 7794997
什么是DOI,文献DOI怎么找? 3437934
关于科研通互助平台的介绍 2561228
邀请新用户注册赠送积分活动 2484609